Louis M Aledort

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc The 5, 10 methylenetetrahydrofolate reductase C677T mutation and risk of fetal loss: a case series and review of the literature
    Ivy Altomare
    Mount Sinai Medical Center, 1 Gustave L, Levy Pl, New York, USA
    Thromb J 5:17. 2007
  2. ncbi request reprint Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little
    L M Aledort
    The Mount Sinai Medical Center, New York, NY 10029, USA
    Semin Thromb Hemost 26:189-93. 2000
  3. ncbi request reprint Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 2:861-2. 2004
  4. ncbi request reprint Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    L M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Thromb Haemost 2:1700-8. 2004
  5. ncbi request reprint United States' factor XI-deficiency patients need a safer treatment
    Louis M Aledort
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Am J Hematol 80:301-2. 2005
  6. ncbi request reprint Why thrombin generation? From bench to bedside
    Louis M Aledort
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Pathophysiol Haemost Thromb 33:2-3. 2003
  7. ncbi request reprint Orthopedic outcome studies and cost issues
    Louis M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Semin Thromb Hemost 29:55-60. 2003
  8. ncbi request reprint Can costs of hemophilia products be curtailed? Not as we do business today!
    Louis M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1006, New York, NY 10029 6574, USA
    Thromb Haemost 88:541. 2002
  9. ncbi request reprint HIV and hemophilia
    L M Aledort
    The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY, USA
    J Thromb Haemost 5:607-10. 2007
  10. ncbi request reprint Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura
    L M Aledort
    University Clinics Charite, Berlin, Germany
    Hematology 12:289-95. 2007

Detail Information

Publications34

  1. pmc The 5, 10 methylenetetrahydrofolate reductase C677T mutation and risk of fetal loss: a case series and review of the literature
    Ivy Altomare
    Mount Sinai Medical Center, 1 Gustave L, Levy Pl, New York, USA
    Thromb J 5:17. 2007
    ..The true relationship between methylenetetrahydrofolate reductase C677T homozygosity and risk of recurrent spontaneous abortion is unknown, and it is unclear if women with these mutations should be anticoagulated during pregnancy...
  2. ncbi request reprint Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little
    L M Aledort
    The Mount Sinai Medical Center, New York, NY 10029, USA
    Semin Thromb Hemost 26:189-93. 2000
    ..Data are needed to provide the cost benefit of immune tolerance...
  3. ncbi request reprint Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 2:861-2. 2004
  4. ncbi request reprint Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    L M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Thromb Haemost 2:1700-8. 2004
    ..Nevertheless, this comprehensive pharmacovigilance assessment does not support superior thrombotic safety of rFVIIa and suggests that thrombotic AE risk may be higher in rFVIIa than FEIBA recipients...
  5. ncbi request reprint United States' factor XI-deficiency patients need a safer treatment
    Louis M Aledort
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Am J Hematol 80:301-2. 2005
    ..A review of the experience over 15 years suggests that this product is safe and effective and suggests its potential use in the U.S. The most serious complication of the factor was a slight increase in DIC and thrombotic events...
  6. ncbi request reprint Why thrombin generation? From bench to bedside
    Louis M Aledort
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Pathophysiol Haemost Thromb 33:2-3. 2003
    ..The use of a laboratory test to help define therapeutic regimens, dissect effects of these treatments, and to differentiate them are clearly needed. The current state of the art of thrombin generation is ready to do this...
  7. ncbi request reprint Orthopedic outcome studies and cost issues
    Louis M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Semin Thromb Hemost 29:55-60. 2003
    ..The costs of current prophylaxis regimens will be discussed...
  8. ncbi request reprint Can costs of hemophilia products be curtailed? Not as we do business today!
    Louis M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1006, New York, NY 10029 6574, USA
    Thromb Haemost 88:541. 2002
  9. ncbi request reprint HIV and hemophilia
    L M Aledort
    The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY, USA
    J Thromb Haemost 5:607-10. 2007
  10. ncbi request reprint Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura
    L M Aledort
    University Clinics Charite, Berlin, Germany
    Hematology 12:289-95. 2007
    ..This Phase III study examined the efficacy and safety of Rhophylac (CSL Behring AG, Bern, Switzerland), a highly pure, liquid-stable anti-D preparation, in chronic immune thrombocytopenic purpura (ITP)...
  11. ncbi request reprint Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies
    Louis M Aledort
    Department of Medicine, Mt Sinai Hospital, One Gustave L Levy Place, Box 1006, New York, NY 10029 6574, USA
    Am J Hematol 76:205-13. 2004
    ..15). Two of the 205 patients tested (1%) had neutralizing activity of recombinant human TPO in a biological assay; however, this activity was confirmed to be anti-TPO antibody in only 1 patient...
  12. ncbi request reprint History of haemophilia
    L M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
    Haemophilia 13:1-2. 2007
    ..HD and r products now have similar safety profiles. Several diseases have only HD products for treatment. These products remain important in our treatment armamentarium...
  13. ncbi request reprint Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe?
    Louis M Aledort
    J Thorac Cardiovasc Surg 126:2112-3. 2003
  14. doi request reprint Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
    Jeffrey Bander
    Mount Sinai School of Medicine, Zena and Michael A Wiener Cardiovascular Institute, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Thromb Haemost 108:86-93. 2012
    ..These findings suggest that a portion of the haematologic benefit of AVR may be due to a postoperative decline in ADAMTS-13 rather than solely to relief of AS as previously thought...
  15. doi request reprint FEIBA: a prohemostatic agent
    Caroline Cromwell
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Semin Thromb Hemost 38:265-7. 2012
    ..The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains...
  16. ncbi request reprint The role of porcine factor VIII in the management of unexpected bleeding episodes
    L M Aledort
    Department of Hemophilia, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1006, New York, NY, USA
    Haemophilia 8:17-9; discussion 28-32. 2002
    ..Case studies will be presented that offer important differential diagnoses. The prevalence and indications for the use of this biological replacement therapy will be discussed...
  17. ncbi request reprint Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Haemophilia 14:39-43. 2008
    ....
  18. ncbi request reprint Advances in clotting factor treatment for congenital hemorrhagic disorders
    Michael D Tarantino
    University of Illinois College of Medicine Peoria, Peoria, IL 61614, USA
    Clin Adv Hematol Oncol 2:363-8. 2004
    ..Although this review will focus primarily on clotting factor replacement, the reader may refer to recent discourse on gene therapy for hemophilia...
  19. ncbi request reprint Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody
    Paul E Monahan
    Department of Pediatrics, University of North Carolina at Chapel Hill, North Carolina, USA
    Am J Hematol 77:346-50. 2004
    ..Specific knowledge deficits in need of prospective research were identified with respect to the rational treatment of inhibitor patients...
  20. ncbi request reprint AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
    James B Bussel
    New York Presbyterian Hospital, New York, USA
    N Engl J Med 355:1672-81. 2006
    ..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP...
  21. ncbi request reprint Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies
    Sebastian A Mayer
    Department of Hematology, Box 1006, Mount Sinai Medical Center, One East 100th Street, New York, NY 10029, USA
    Mt Sinai J Med 72:166-75. 2005
    ..In this review, we will cover the multiple etiologic factors for TMAs, with the resultant differential diagnoses, as well as provide insight into the latest pathophysiologic findings and possible implications for treatment...
  22. doi request reprint Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia
    Brett A Sealove
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Stroke Cerebrovasc Dis 17:241-3. 2008
    ..In conclusion, these observations implicate ischemia caused by hemodynamic vascular insufficiency as a possible cause of TGA...
  23. ncbi request reprint Do we need a better test? Can thrombin generation be useful?
    Louis M Aledort
    Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Hematol Rep 3:75-6. 2004
  24. ncbi request reprint Making a therapeutic choice: human versus recombinant fractions - can we do it?
    L M Aledort
    Mt Sinai Medical Center, New York, NY 10029, USA
    Haemophilia 7:1-3. 2001
    ..These issues and others are reviewed in the context of making a therapeutic choice...
  25. ncbi request reprint End-stage liver disease in persons with hemophilia and transfusion-associated infections
    James J Goedert
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
    Blood 100:1584-9. 2002
    ..04-fold (95% CI, 1.03-1.06) per year of age. Thus, HIV is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4(+) lymphocytes, or older age...
  26. ncbi request reprint Platelet bleeding disorders and approach to their management
    Louis M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1006, New York, NY 10029, USA
    Curr Hematol Rep 4:85-7. 2005
  27. doi request reprint Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 371:395-403. 2008
    ..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP...
  28. ncbi request reprint Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990
    James J Goedert
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    Am J Epidemiol 165:1443-53. 2007
    ....
  29. ncbi request reprint Haemostasis: from bench to bedside
    Simon A Brown
    Haemophilia 8:685-93. 2002
  30. ncbi request reprint Molecular challenges and viral diseases
    Simon A Brown
    Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, London, UK
    Haemophilia 9:727-37. 2003
  31. ncbi request reprint Therapeutic choices in the current millennium: hemophilia workshop highlights
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA
    Pediatr Blood Cancer 45:611-5. 2005
    ..This paper provides a summary of the discussions at these workshops. Despite the progress made in the management of patients with hemophilia, the workshop highlighted the fact that there were still many unanswered questions...
  32. ncbi request reprint Current issues facing coagulationists--meeting report
    S A Brown
    Katharine Dormandy Haemophilia and Haemostasis Unit, Royal Free Hospital, London, UK, and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Haemophilia 12:115-23. 2006
  33. ncbi request reprint AIDS, hepatitis and hemophilia
    L M Aledort
    Mount Sinai School of Medicine, New York, NY, USA
    J Thromb Haemost 2:521. 2004
  34. ncbi request reprint Can managed care support hemophilia in the 21st century?
    Louis M Aledort
    Am J Hematol 79:172-3. 2005